Raj Devarajan, M.D. Medical Advisor · Gastroenterologist · Psychiatrist · Physician Executive 9 MacGregor Way, Acton, MA 01720 · (978) 857-5032 · Rajdevarajan1@gmail.com
E X E C UT IV E
PR OFILE
There may be no other practicing physician in the United States who is board-certified in Gastroenterology, Internal Medicine, Adult Psychiatry and Neurology, and Child and Adolescent Psychiatry - and is actively publishing research at the GI-endocrinology interface. That is Dr. Raj Devarajan’s opening sentence, and it is not a credential list. It is a description of the exact advisory profile of someone who can speak with clinical authority across multiple practice disciplines, the MedTech GI device pipeline, and the endocrinological dimensions of disease that connect them. Over a 30-year career Dr. Devarajan performed more than 60,000 endoscopic procedures, founded and scaled a fourentity physician-owned practice group, led hospital medical staff governance, and served as president of three professional medical associations. He now applies this breadth as Global Medical Advisor at Cristcot, where he is coauthoring peer-reviewed research across five major international conferences.
B OA R D
&
A D V IS OR Y
C OMPE T EN C IE S
▪ Clinical Governance & Quality Oversight ▪ Healthcare Innovation & Emerging Technologies ▪ Medical Affairs & Regulatory Strategy ▪ Physician Enterprise Leadership
B OA R D
▪ Patient Safety & Risk Management ▪ Stakeholder & Executive Engagement ▪ Adult Psychiatry and Neurology ▪ Healthcare Policy & Compliance
C E R T IFIC A T IONS
Gastroenterology · Internal Medicine · Adult Psychiatry and Neurology · Child and Adolescent Psychiatry
A D V IS OR Y
&
EX E C UT IV E
EX P ER IE N C E
Global Medical Advisor · Cristcot 2023 - Present ▪ Advising on clinical strategy, product and pipeline development, and medical affairs for global healthcare initiatives ▪ Contributing to governance frameworks, evidence generation, and stakeholder engagement at the executive level ▪ Co-authoring peer-reviewed research accepted at ACG 2025 and submitted to DDW 2026, UEG 2026, ENDO 2026, and ACG 2026 ▪ Co-inventor and patent holder on an FDA Phase 3 investigational drug currently advancing toward New Drug Application (NDA) submission
Founder & President · Middlesex Gastroenterology PC / Middlesex Endoscopy Center / Commonwealth Anesthesia / Middlesex Pathology Acton, MA 1994 - 2023
▪ Built and led an integrated, physician-owned multi-entity gastroenterology practice serving the greater Concord/Acton region of Massachusetts for nearly three decades ▪ Established ERCP programs at Emerson Hospital and Nashoba Valley Medical Center, serving as a regional center of clinical excellence ▪ Performed 60,000+ endoscopic procedures; oversaw clinical operations, quality assurance, compliance, and physician governance across four affiliated entities ▪ Led the strategic preparation of Middlesex Gastroenterology PC and two additional Massachusetts practices for sale to private equity, overseeing valuation, due diligence, and transaction readiness across all three organizations
ME D IC A L
LE A D E R S H IP
&
GOV ER N A N C E
President of Medical Staff
President
Emerson Hospital · 2015 - 2017
American Association of Gastroenterologists of Indian Origin · 2015 - 2020
President Massachusetts Gastroenterology Association · 2015 2017
E D U C A T ION
&
Cristcot · Boston Scientific · Pentax Corporation
T R A IN IN G
M.B.B.S., Madras Medical College Residency, Adult Psychiatry - Yale University Fellowship, Child Psychiatry - Harvard Medical School Fellowship, Internal Medicine & Gastroenterology - Tufts University
S E LE C TE D
Industry Consultant
R E C EN T
1984 1988 1990 1994 1994
P UB LIC A T ION S
&
P R E SE N T AT ION S
▪ ACG 2025 (Accepted): Three abstracts and posters accepted at the American College of Gastroenterology Annual Scientific Meeting - evaluating clinical outcomes in CESSA, patient-reported outcomes (PRO) in CESSA, and pharmacokinetic (PK) profiling of a novel GI intervention ▪ DDW 2026 (Accepted): Endocrinology abstract accepted and oral presentation delivered - investigating surreptitious corticosteroid use as a confounding variable in CESSA diagnosis, with direct implications for treatment protocol design ▪ UEG 2026 (Submitted): Abstract examining CESSA topline outcomes submitted to United European Gastroenterology Week - pending acceptance; findings address a diagnostic gap relevant to European clinical guidelines ▪ ENDO 2026 (Submitted): Abstract submitted to the Endocrine Society Annual Meeting - modeling dual-dose cosyntropin stimulation to improve adrenal insufficiency detection accuracy in GI-endocrine overlap presentations ▪ ACG 2026 (Submitted): Two abstracts submitted - analyzing concomitant medication subgroups as predictors of CESSA outcomes, and identifying disease characteristics as independent predictors; together forming a comprehensive evidence base for clinical decision support